Sleeping sickness, also known as African trypanosomiasis, is a parasitic disease perpetuated by Trypanosoma brucei, and mainly affects sub-Saharan Africa – resulting in approximately 9,000 deaths a year. Researchers from Trinity College Dublin have found a new potential tool for early diagnosis – or even treatment – of the disease by solving an old riddle: why do camels infected with T. brucei excrete pungent redbrown urine? (1).
According to Anne McGettrick, Senior Research Fellow at Trinity College Dublin and lead author of the paper, it all started in a pub, over a pint of cold Guinness… “Luke O’Neill, Professor of inflammation at Trinity College Dublin, had just published a paper in Nature showing that the metabolite, succinate, acted as an immune modulator,” says McGettrick. “And he was chatting in the pub one evening with Derek Nolan, a molecular parasitologist at Trinity, who mentioned that T. Brucei produces high levels of certain metabolites in the bloodstream of infected patients – and camels.” Researchers had always thought that the metabolites were simply a byproduct of their metabolism, but Nolan wondered if they might play a role in the ability of these parasites to evade the immune response. “O’Neill agreed to test some of these metabolites to see if they had any effect on the innate immune response of cells in the laboratory,” says McGettrick. The testing unearthed a metabolic by-product of T.Brucei activity known as indolepyruvate, which alters the composition of the camel urine – affecting its color and odor. “The advantage of the parasite excreting indolepyruvate is that it modulates the inflammatory and immune responses of the host – especially at the peaks of infection. This prolongs host survival and thereby potentiates transmission of the parasite to the tsetse fly, which ensures it can complete its life cycle,” says McGettrick. “This is the first demonstration of a metabolite, produced by a parasite, interfering with the host immune response.” The researchers hope their work will open the door to new tests for early diagnosis and treatments for sleeping sickness – with indolepyruvate as a potential target. In addition, McGettrick believes the research could open up the possibility that other metabolites, produced by invading pathogens, could modulate the immune response.
Newsletters
Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.
References
- AF McGettrick et al., “Trypanosoma brucei metabolite indolepyruvate decreases HIF-1α and glycolysis in macrophages as a mechanism of innate immune evasion”, Proc Natl Acad Sci USA, 113, 48 (2016).
